Sale!

CJC-1295 NO-DAC (MOD GRF 1-29)

In stock

$21.99$24.99

Concentration
2 mg per vial
Purchase this product now and earn 22 Points!

This product is prepared for LABORATORY RESEARCH USE ONLY and may not be used for other purposes.

-
+

Free & Fast
Shipping

Earn
Rewards

Excellent
Service

Properties

Molecular Formula C152H252N44O42
Molecular Weight 3367.9
Monoisotopic Mass 3365.8935782
Polar Area 1450
Complexity 7710
XLogP -10.7
Heavy Atom Count 238
Hydrogen Bond Donor Count 52
Hydrogen Bond Acceptor Count 48
Rotatable Bond Count 118
Physical Appearance Fine White Lyophilized Powder
Stability Lyophilized protein is to be stored at -20°C. It is recommended to aliquot the reconstituted (dissolved) protein into several discrete vials in order to avoid repeated freezing and thawing. Reconstituted protein can be stored at 4°C
PubChem LCSS CJC-1295 NO-DAC (MOD GRF 1-29) Laboratory Chemical Safety Summary

Identifiers

CID 56841945
InChI InChI=1S/C152H252N44O42/c1-22-79(15)118(194-125(214)84(20)171-135(224)107(68-115(206)207)181-124(213)81(17)169-126(215)91(155)65-87-41-45-89(201)46-42-87)147(236)189-106(66-86-34-25-24-26-35-86)141(230)196-120(85(21)200)149(238)180-99(51-54-114(158)205)132(221)190-111(72-199)145(234)185-105(67-88-43-47-90(202)48-44-88)140(229)178-96(40-33-59-168-152(164)165)128(217)177-94(37-28-30-56-154)133(222)193-117(78(13)14)146(235)187-100(60-73(3)4)134(223)170-82(18)123(212)175-97(49-52-112(156)203)130(219)183-103(63-76(9)10)138(227)191-109(70-197)143(232)172-83(19)122(211)174-95(39-32-58-167-151(162)163)127(216)176-93(36-27-29-55-153)129(218)182-102(62-75(7)8)137(226)184-101(61-74(5)6)136(225)179-98(50-53-113(157)204)131(220)186-108(69-116(208)209)142(231)195-119(80(16)23-2)148(237)188-104(64-77(11)12)139(228)192-110(71-198)144(233)173-92(121(159)210)38-31-57-166-150(160)161/h24-26, 34-35, 41-48, 73-85, 91-111, 117-120, 197-202H, 22-23, 27-33, 36-40, 49-72, 153-155H2, 1-21H3, (H2, 156, 203)(H2, 157, 204)(H2, 158, 205)(H2, 159, 210)(H, 169, 215)(H, 170, 223)(H, 171, 224)(H, 172, 232)(H, 173, 233)(H, 174, 211)(H, 175, 212)(H, 176, 216)(H, 177, 217)(H, 178, 229)(H, 179, 225)(H, 180, 238)(H, 181, 213)(H, 182, 218)(H, 183, 219)(H, 184, 226)(H, 185, 234)(H, 186, 220)(H, 187, 235)(H, 188, 237)(H, 189, 236)(H, 190, 221)(H, 191, 227)(H, 192, 228)(H, 193, 222)(H, 194, 214)(H, 195, 231)(H, 196, 230)(H, 206, 207)(H, 208, 209)(H4, 160, 161, 166)(H4, 162, 163, 167)(H4, 164, 165, 168)/t79-, 80-, 81+, 82-, 83-, 84-, 85+, 91-, 92-, 93-, 94-, 95-, 96-, 97-, 98-, 99-, 100-, 101-, 102-, 103-, 104-, 105-, 106-, 107-, 108-, 109-, 110-, 111-, 117-, 118-, 119-, 120-/m0/s1
InChIKey XOZMWINMZMMOBR-HRDSVTNWSA-N
Isomeric SMILES CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
Canonical SMILES CCC(C)C(C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)O)C(=O)NC(CCC(=O)N)C(=O)NC(CO)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)N)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(C)NC(=O)C(CC3=CC=C(C=C3)O)N
IUPAC Name (3S)-4-[[(2S)-1-[[(2S, 3S)-1-[[(2S)-1-[[(2S, 3R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S, 3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1, 5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1, 5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1, 5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid
CAS 446262-90-4

2D Structure

Generated by Extreme Peptide with Open Babel, version 2.3.1, http://openbabel.org (accessed June 28, 2022)

CJC-1295 NO-DAC (MOD GRF 1-29) 2D molecular structure vector generated with oBabel

Description

CJC-1295 no DAC is a synthetic peptide developed to be an analogy of growth hormone releasing hormone (GHRH)1. The 29 amino acid sequence is derived from GRF(1-29), a naturally occurring growth hormone releasing factor. As its name implies, CJC-1295 no DAC lacks the ‘drug affinity complex’ described below2. This structural difference infers a shorter peptide half-life than its DAC-inclusive counterpart, which is elicits a GH release profile that more closely reflects what occurs in nature.

CJC-1295 no DAC is reported to be a potent agent for the stimulation of pulsatile growth hormone (GH) and IGF-1 release3. These biochemical actions have been shown to result in the promotion of lean body mass, enhanced strength, increased appetite, and an improved quality of sleep in animal test subjects4.

Product Comparison

In spite of having a similar site of action, CJC-1295 no DAC (and CJC-1295 with DAC) does not stimulate GH production using the same biochemical pathway as the popular GH secretagogue GHRP-65. In light of this observation, it has been possible for researchers to administrate CJC-1295 species and GHRP-6 concurrently in order to achieve an additive positive effect on GH release.

Drug Affinity Complex

The drug affinity complex (DAC) is a chemical group fixed to CJC-1295 DAC that helps the peptide escape degradation by natural enzymes. By adding a component that gives CJC-1295 an affinity for albumin2, a naturally occurring protein in blood plasma, the peptide can achieve a much longer systemic half-life.

Preference for a long or short peptide half-life depends entirely on the research application of these agents.

Synonyms:

CJC-1295; CJC-1295 no DAC; CJC-1295 without DAC; Modified Growth Releasing Factor aminos 1-29; Modified GRF (1-29); Mod GRF 1-29; Tetrasubstituted GRF (1-29);


Peer-Reviewed Sources:

  1. Sackmann-Sala, L., Ding, J., Frohman, L. A., & Kopchick, J. J. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 19(6), 471-477. ↩︎
  2. Beals, J. M., & Shanafelt, A. B. (2006). Enhancing exposure of protein therapeutics. Drug Discovery Today: Technologies, 3(1), 87-94. ↩︎
  3. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. ↩︎
  4. Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294. ↩︎
  5. Cordido, F., Penalva, A., Dieguez, C., & Casanueva, F. F. (1993). Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. The Journal of Clinical Endocrinology & Metabolism, 76(4), 819-823. ↩︎

All literature, information, and data, provided on this website are for informational and educational purposes only.

Accurate research is our priority.

Same Day Shipping
We offer same day shipping on all orders of in stock items placed before 12:00pm EST.
Dedicated Service
Our team is readily available to assist with all of your customer service requests.
Free Shipping
We've got you covered! Free shipping is available on any order over $50.
Earn Rewards
Earn points every time you buy from us and use them towards future orders!
Extreme Peptide vial with logo and indicators